

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT WITH HARBOUR BIOMED (SHANGHAI) CO., LTD. FOR BATOCLIMAB (HBM9161)

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that on 10 October 2022, CSPC NBP Pharmaceutical Co., Ltd.* (“**NBP Pharma**”) (石藥集團恩必普藥業有限公司), a wholly-owned subsidiary of the Company, entered into an exclusive license agreement (the “**Agreement**”) with Harbour Biomed (Shanghai) Co., Ltd.* (“**Shanghai HBM**”), pursuant to which NBP Pharma obtained an exclusive license from Shanghai HBM to develop, manufacture and commercialize batoclimab (HBM9161) (the “**Product**”) in Greater China (including mainland China, Hong Kong, Macau and Taiwan) (the “**Territory**”).

In consideration for the exclusive license for the Product in the Territory, NBP Pharmaceutical agreed to pay Shanghai HBM an upfront payment of RMB150 million, up to RMB50 million in potential technology milestone payments, up to RMB400 million in potential development and regulatory milestone payments, and up to US\$57.5 million (approximately RMB411 million) in potential sales milestone payments. NBP Pharma also agreed to pay Shanghai HBM tiered royalties based on annual net sales of the Product in the Territory.

Batoclimab (HBM9161), one of the core products of Shanghai HBM, is designed as a fully human monoclonal antibody that selectively binds to and inhibits the neonatal FcRn. FcRn plays a pivotal role in preventing the degradation of IgG antibodies. High levels of pathogenic IgG antibodies drive many autoimmune diseases. As the clinically most advanced FcRn inhibitor being developed in Greater China, batoclimab (HBM9161) has potential to be a breakthrough treatment for a wide spectrum of autoimmune diseases in Greater China. The current development of batoclimab (HBM9161) is initially focused on myasthenia gravis (MG), immune thrombocytopenia (ITP), neuromyelitis optical spectrum disorder (NMOSD), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus vulgaris (PV).

Shanghai HBM is a wholly-owned subsidiary of HBM Holdings Limited (“**HBM Holdings**”), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 02142). HBM Holdings is principally engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its proprietary antibody technology platform Harbour Mice[®], integrated with the single B cell cloning platform, form the engine for the research and development of innovative therapeutic antibodies.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 10 October 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

** For identification purposes only*